Vaccination of Non-Small Cell Lung Cancer Patients Against Mutated K-Ras: A Pilot Trial
- Determine whether a specific T-cell response can be induced in patients with stage
IB-IV non-small cell lung cancer treated with mutant K-ras peptide vaccine (limited to
the specific K-ras peptide mutation in their tumors) and sargramostim (GM-CSF).
- Determine whether skin test reactivity or HLA type correlates with the induction of
anti-K-ras immune responses in patients treated with this regimen.
- Determine the toxicity of this regimen in these patients.
OUTLINE: Patients receive sargramostim (GM-CSF) intradermally (ID) on days 1-10 beginning a
maximum of 6 months after complete surgical resection. Patients receive mutant K-ras peptide
vaccine (limited to the specific K-ras mutation in their tumors) ID on day 7. Treatment
repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable
Patients are followed at 4 and 12 weeks.
PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study within 18
Primary Purpose: Treatment
Lee M. Krug, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|